display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic-recurrent HNSCC (mHNSCC)
mHNSCC - L1 - PDL1 positive
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab alone KEYNOTE-048 ... KEYNOTE-048 ...
pembrolizumab plus 5FU plus platin KEYNOTE-048 ... KEYNOTE-048 ...

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons